CAR-T cell therapy for hard-to-treat autoimmune diseases
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Eyes & vision, Genetic & congenital, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and weigh at least 45 kg (about 99 lbs).
- You have been diagnosed with one of the listed autoimmune conditions and have not responded to multiple standard treatments.
- You are in a stable phase of treatment (no recent major changes in medications) for at least 4 weeks before joining.
- You agree to use effective contraception (but not hormone-based methods like birth control pills or rings) during the study.
- For certain diseases, you must have active disease symptoms (like new or worsening ulcers, joint swelling, or organ problems).
- You are willing and able to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.